Wave Life Sciences reported an updated cut of data from its early-stage study of an RNA editing treatment for alpha-1 antitrypsin deficiency, suggesting that it can dose its genetic therapy monthly.
Paul Bolno, Wave Life Sciences CEO
May 19, 2026 11:19 AM EDT
Wave aims for monthly dosing with RNA editing treatment for AATD
Lei Lei Wu
News Reporter
Immunovant shares climbed on results an analyst deemed “compelling” in tough-to-treat arthritis. Elsewhere, Wave’s pioneering…
NYT: A new drug for a subset of patients 'tells us that ALS is treatable', expert says.
Avalo reported study success in what’s proven to be a tough-to-treat skin disease. Elsewhere, BioNTech announced plans to close…
Stay up to date with notifications from The IndependentNotifications can be managed in browser preferences.Jump to contentThank…
US regulators are willing to reconsider using a Phase 3 study of tab-cel as the basis for an approval, after previously rejecting…
Alzheimer's drug rollout letdown, a China-based heart drug startup, and more biotech news from The Readout
